Indication Avastin in Ophthalmology

1. Ahmadieh, H., Ramezani, A., Shoeibi, N. et al.: Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol, 246(4), 2008, 483–9.

2. Algvere, P.V., von Wendt, G., Gudmundsson, J. et al.: Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin). Acta Ophthalmol, v tisku.

3. Anselem, L., Montero, J., Diaz-Llopis, M. et al.: Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol., 144(1), 2007, 122–4.

4. Arevalo, J.F., Sanchez, J.G., Wu, L. et al.: Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration at Twenty-four Months: The Pan-American Collaborative Retina Study Group. Ophthalmology, 2010.

5. Arevalo, J.F., Sanchez, J.G., Wu, L. et al.: Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.Ophthalmology, 116(8), 2009, 1488–97.

6. Augustine, A.J., Puls, S., Offermann, I.: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina, 27(2), 2007, 133–40.

7. Avery, R.L.: Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina, 26(3), 2006, 352–4.

8. Avery, R.L., Pieramici, D.J., Rabena, M.D. et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology, 113, 2006, 363–372.

9. Bakri, S.J., Donaldson, M.J., Link, T.P.: Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye, 20(12), 2006, 1474–5.

10. Cornish, K.S., Ramamurthi, S., Saidkasimova, S. et al.: Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye, 23(4), 2009, 979–81.

11. Dastjerdi, M.H., Al-Arfaj, K.M., Nallasamy, N. et al.: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol, 127(4), 2009, 381–9.

12. Doležalová, J., Karel, I., Hallová, H.: Naše dvouleté zkušenosti s léčbou vlhké formy věkem podmíněné makulární degenerace bevacizumabem (Avastin). Čes. a Slov. Oftal., 66 (1), 2010, 10–14.

13. Entezari, M., Ramezani, A., Safavizadeh, L. et al.: Resolution of macular edema in Coats disease. Indian J Ophthalmol., 58(1), 2010, 80–2.

14. Fang, X., Sakaguchi, H., Gomi, F. et al.: Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol, 86(7), 2008, 800–5.

15. Gharbiya, M., Allievi, F., Recupero, V. et al.: Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina, 29(6), 2009, 740–9.

16. Grisanti, S., Biester, S, Peters, S. et al.: Intravitreal bevacizumab (avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol, 142, 2006, 158–60.

17. Gunther, J.B., Altaweel M.M.: Bevacizumab for the treatment of ocular disease. Surv Ophthalmol, 54(3), 2009, 372–400.

18. Honda, S., Hirabayashi, H., Tsukahara, Y. et al.: Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 246(7), 2008, 1061–3.

19. Chan, W.M., Lai, T.Y., Liu, D.T. et al.: Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six month results of a prospective pilot study. Ophthalmology, 114(12), 2007, 2190–6.

20. Chanana, B., Azad, R.V., Patwardhan, S. et al.: Role of intravitreal bevacizumab in the management of Eales disease. Int Ophthalmol, 30(1), 2010, 57–61.

21. Iliev, M.E., Domig, D., Wolf-Schnurrbursch, U. et al.: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol, 142(6), 2006, 1054–6.

22. Isaacs, T.W., Barry, C.: Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol, 34(8), 2006, 802–3.

23. Jonas, J.B., Spandau, U.H., Schlichtenbrede, F.: Intravitreal bevacizumab for filtering surgery. Ophthalmic Res, 39(2), 2007, 121–2.

24. Kahook, M.Y., Schuman, J.S., Noecker, R.J.: Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging, 37(2), 2006, 144–6.

25. Kaiser, P.K., Boyer, D.S., Garcia, R. et al.: Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 116(4), 2009, 747–59.

26. Kitnarong, N., Chindasub, P., Metheetrairut, A.: Surgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther. 25(5), 2008, 438–43.

27. Lin, C.J., Hwang, J.F., Chen, Y.T. et al.: The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina, 30(4), 2010, 617–22.

28. Mintz-Hittner, H.A., Kuffel, R.R. Jr.: Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina, 28(6), 2008, 831–8.

29. Moshfeghi, A.A., Rosenfeld, P.J., Puliafito, C.A. et al.: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology, 113(11), 2006, 1–12.

30. Myung, J.S., Bhatnagar, P., Spaide, R.F. et al.: Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularisation in pseudoxanthoma elasticum. Retina, 30(5), 2010, 748–55.

31. Neri, P., Salvolini, S., Mariotti, C. et al.: Long-term control of choroidal neovascularisation secondary to angioid streaks treated with intravitreal bevacizumab (Avastin). Br. J. Ophthalmol.93(2), 2009, 155–8.

32. Ornek, K., Ornek, N.: Intravitreal bevacizumab treatment for refraktory diabetic macular oedema. J Ocul Pharmacol Ther, 24(4), 2008, 403–7.

33. Palmer, E.A, Hardy, R.J., Dobson, V. et al.: 15-year outcomes following threshold retinopathy of prematurity: final results from Multicenter Trial of Cryotherapy for Retinopathy of Prematurity. Arch Ophthalmol, 123, 2005, 311–18.

34. Priglinger, S.G., Wolf, A.H., Kreutzer, T.C. et al.: Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six month results of a prospective trial. Retina, 27(8), 2007, 1004–12.

35. Ronan, S.M., Yoganathan, P., Chien, F.Y. et al.: Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina, 27(5), 2007, 535–40.

36. Rosenfeld, P.J., Moshfeghi, A.A., Puliafito, C.A.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 36(4), 2005, 331–5.

37. Sawa, M., Gomi, F., Tsujikawa, M. et al.: Long-term results of intravitreal bevacizumab injection for choroidal neovascularisation secondary to angioid streaks. Am J Ophthalmol, 148(4), 2009, 584–590.

38. Schmidinger, G., Maar, N., Bolz, M. et al.: Repeated intravitreal bevacizumab (Avastin(R)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol, v tisku.

39. Sivak-Callcott, J.A., O’Day, D.M., Gass, D.M. et al.: Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology, 108, 2001, 1767–76.

40. Soheilian, M., Ramezani, A., Obudi, A. et al.: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology, 116(6), 2009, 1142–50.

41. Spaide, R.F., Laud., K., Fine, J.F.F. et al.: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina, 26, 2006, 383–90.

42. Vasudev, D., Blair, M.P., Galasso, J. et al.: Intravitreal bevacizumab for neovascular glaucoma.J Ocul Pharmacol Ther, 25(5), 2009, 453–8.

43. Weinberger, A.W., Thiel, M., Mohammadi, B. et al.: Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol, 144(2), 2007, 294–6.

44. Wiegand, T.W., Rogers, A.H., McCabe, F. et al.: Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. Br. J. Ophthalmol., 93(1), 2009, 47–51.

45. Wu, L., Arevalo, J.F., Berrocal, M.H. et al.: Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina, 29(10), 2009, 1396–403.

46. Wu, L., Arevalo, J.F., Berrocal, M.H. et al.: Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusions: results of the pan American collaborative retina study group at 24 months.Retina, 30(7), 2010, 1002–11.

47. Wu, L., Arevalo, J.F., Maia, M. et al.: Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol, 53(2), 2009, 125–30.

48. Wu, L., Martinez-Castellanos, M.A., Quiroz-Mercado, H. et al.: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol, 246(1), 2008, 81–7.